롱

BD1 BARD LIFE SCIENCES ENTERS TRADING HALT!!!

업데이트됨

ASX: BD1 > Bard Life Sciences

After announcing successful trials to the Market for NON INVASIVE Breast/Lung/Prostrate early detection CANCER tests, a VERY bullish event has materialised in the form of a TRADING HALT in expectation of a Market sensitive Announcement.

This could mean many things however the confluence of News, events, price action and Chart MAGIC points to a VERY HIGH PROBABILITY of an EXPLOSIVE move in the share Price.

Probability is heavily stacked to the UPSIDE and a large GAP in Price is expected on resumption of Trade in ASX: BD1 with likely outliers in Stock Price to manifest over the coming weeks. Expect Volatility.

This presents the sumptuous prospect of both Trading opportunities for the short term Speculator as well as the patient alpha seeking value based holder.

Assess the RISK, know your GOALS, set your Targets and STICK TO YOUR PLAN.

Always DYOR.

Disclosure: I AM a Long Holder of BD1

BD1's amazing GOOD NEWS story can be found here>

bard1.com/

액티브 트레이드

Today (8/11/18) brings further important information to light re: the Trading halt in BD1.

Whilst Speculators and the leveraged/over committed short term 'baitfish' Investor may be holding their bloodied heads in their hands for today and are awaiting the Paramedics, those that have done their Due Diligence on this promising HUGE potential VALUE stock and were positioned prior to the Announcement awoke to the pleasant news that they have an enforced opportunity to average down by way of a NON RENOUNCEABLE Entitlement issue.

'Long believers' have been generously rewarded under the Entitlement Issue whereby eligible shareholders will be entitled to subscribe for one (1) new share for every five (5) existing shares held at the record date at the offer price of $0.02 per share. The Entitlement Issue offer price of $0.02 per share represents a 39% discount to the last traded price of ASX:BD1 shares of $0.033 on 7 November 2018.

"The funds raised from the Entitlement Issue are intended to be used to advance development of the BARD1 diagnostics pipeline, ongoing research activities, commercial initiatives and for general working capital purposes." - BD1 ASX Announcement found here>

clients3.weblink.com.au/pdf/BD1/02045679.pdf

Although this puts on hold my premature excitement for an "EXPLOSIVE" move in SP, my original contention holds and my SOLID conviction on this stock remains.

At these prices I now hold 20% more stock for chicken feed.

I expect my 'BD1 Chooks' will be laying SOLID GOLD eggs and shitting DIAMONDS into and throughout 2019 and beyond.

...potential early diagnoses of multiple Cancers; just think about the scale of the Market BD1 are targeting here...

Always DYOR.